更新于：2024-06-30
Mepivacaine Hydrochloride
盐酸甲哌卡因
更新于：2024-06-30
概要
基本信息
原研机构- |
最高研发阶段批准上市 |
首次获批日期 (1956-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看首次获批时间轴
结构
分子式C15H23ClN2O |
InChIKeyRETIMRUQNCDCQB-UHFFFAOYSA-N |
CAS号1722-62-9 |
关联
69
项与 盐酸甲哌卡因 相关的临床试验Impact Evaluation of Perioperative Locoregional Analgesia on Persistent Postoperative Pain in Children After Orthopedic Surgery for Traumatology : a Prospective, Single Center, Randomised Controlled Study.
Onset of Sensory Blockade in Ultrasound-Guided Ankle Block With Mepivacaine Versus Bupivacaine: A Randomized Non-Inferiority Clinical Trial
Mepivacaine Versus Bupivacaine Spinal Anesthesia for Same Day Discharge Following Total Knee Arthroplasty
100 项与 盐酸甲哌卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸甲哌卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸甲哌卡因 相关的专利（医药）
登录后查看更多信息
2,019
项与 盐酸甲哌卡因 相关的文献（医药）2024-03-01Anaesthesia and intensive care
Retinal artery occlusion after ophthalmic surgery under regional anaesthesia: A narrative review
Review
作者: Chua, Alfred Wy ; Kumar, Chandra M ; Chua, Matthew J ; Harrisberg, Brian P
Two recent cases of central retinal artery occlusion under otherwise uncomplicated sub-Tenon’s block that resulted in significant visual loss after cataract surgery prompted us to undertake a literature review of such cases. We identified 97 cases of retinal artery occlusion after ophthalmic surgery under regional anaesthesia that had no immediate signs of block-related complications. These occurred after various intraocular (87%) and extraocular (13%) operations, across a wide range of ages (19–89 years) on patients with (59%) or without (39%) known risk factors. The anaesthetic techniques included 40 retrobulbar blocks, 36 peribulbar blocks, 19 sub-Tenon’s blocks, one topical anaesthetic and one unspecified local anaesthetic. Different strengths of lidocaine, bupivacaine, mepivacaine and ropivacaine, either alone or in various combinations, were used. The details of the anaesthetic techniques were often incomplete in the reports, which made comparison and analysis difficult. Only nine cases had their cause (optic nerve sheath injury) identified, while the mechanism of injury was unclear in the remaining patients. Various mechanisms were postulated; however, the cause was likely to be multifactorial due to patient, surgical and anaesthetic risk factors, especially in those with compromised retinal circulation. As there were no definite risk factors identified, no specific recommendations could be made to avoid this devastating outcome. We have provided rationales for some general considerations, which may reduce this risk, and propose anaesthetic options for ophthalmic surgery on the fellow eye if required, based both on our literature review and our personal experience.
Regional anesthesia and pain medicine
Mepivacaine dosing for spinal anesthesia in pediatric orthopedic surgery: a retrospective chart review
Article
作者: Lauzadis, Justas ; Sheetz, Miriam ; Carley, Michelle ; Zhong, Haoyan ; DelPizzo, Kathryn
Background:
Mepivacaine is an intermediate-acting local anesthetic used for spinal anesthesia in adults. Currently, there are no published dosing guidelines for spinal mepivacaine in patients under age 18.
Aims:
The purpose of this study is to describe the clinically used doses of mepivacaine by weight and age for orthopedic surgery in pediatrics.
Methods:
We performed a retrospective chart review of patients aged 0–18 who received mepivacaine for spinal anesthesia from 2016 to 2022. We performed a secondary analysis for patients aged 0–18 who received spinal anesthesia with bupivacaine or chloroprocaine.
Results:
The data extraction yielded 3627 single-shot mepivacaine spinals. Patient age ranged from 5 to 18 years. Median dosage in milligrams/kilograms (mg/kg) of mepivacaine was calculated for each age group. Our analysis revealed that dosage in mg/kg decreased by patient age and began to plateau at age 15. Bupivacaine was the most common single-shot spinal agent in patients under age 10. After age 10, mepivacaine was more common. Chloroprocaine began to be used in patients older than 8 years.
Conclusions:
We describe mepivacaine dosage as a function of age and weight in patients younger than 18 years. As age and weight increased, a lower dose of mepivacaine per kg was administered for spinal anesthesia.
2024-02-01European journal of medicinal chemistry
Design, synthesis, and pharmacological evaluation of indole-piperidine amides as Blood−brain barrier permeable dual cholinesterase and β-secretase inhibitors
Article
作者: Nuthakki, Vijay K ; Sharma, Ankita ; Wadje, Bhagyashri N ; Banoo, Razia ; Bharate, Sandip B
Heterocyclic compounds play a crucial role in the discovery of therapeutics. Alzheimer's disease (AD) is an unfathomable sporadic neurodegenerative disorder that involves multiple pathological pathways. The failure of current single-target small molecules to address AD's underlying causes has prompted interest in discovering multi-target directed ligands (MTDLs) to slow down the disease's progression. Herein we report the synthesis and biological evaluation of indole-piperidine amides as MTDLs for AD. The 5,6-dimethoxy-indole N-(2-(1-benzylpiperidine) carboxamide (23a) inhibits hAChE and hBACE-1 with IC50 values of 0.32 and 0.39 μM, respectively. The MTDL 23a is a mixed-type inhibitor of both hAChE and hBACE-1 with Ki values of 0.26 μM and 0.46 μM, respectively. The MD simulation studies revealed that both AChE and BACE-1 experience minor conformational changes on binding with 23a. In the PAMPA-BBB assay, analog 23a demonstrated CNS permeability, indicating the possibility for future investigation in preclinical models of AD.
100 项与 盐酸甲哌卡因 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | - | - | 1956-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 臂丛神经病 | 临床1期 | 中国 | 2014-04-04 | |
| 糖尿病性神经病变 | 临床前 | 美国 | - | |
| 疱疹后神经痛 | 临床前 | 美国 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 154 | (Low-Dose Bupivacaine) | 網繭鏇憲鹽膚顧範網憲(鏇網獵觸窪顧憲襯構壓) = 壓觸膚壓艱艱簾蓋願鹹 網餘餘構廠構膚憲鏇鹹 (遞觸簾憲醖襯醖蓋獵觸, 膚鹹淵淵顧糧齋餘壓襯 ~ 製淵淵衊觸餘製廠齋製) 更多 | - | 2021-08-12 | ||
(Mepivacaine) | 網繭鏇憲鹽膚顧範網憲(鏇網獵觸窪顧憲襯構壓) = 糧鏇餘繭艱窪鹹鏇廠蓋 網餘餘構廠構膚憲鏇鹹 (遞觸簾憲醖襯醖蓋獵觸, 積醖壓範獵顧選網鏇襯 ~ 獵鹽廠餘鏇觸憲範鏇遞) 更多 | ||||||
临床4期 | 159 | (Isobaric Bupivacaine) | 蓋製廠淵壓鏇窪糧淵膚(積淵獵鏇範鏇願膚獵衊) = 夢鹹廠醖範鑰簾襯衊餘 窪襯憲餘網獵窪繭鹹範 (選製齋蓋憲選餘鏇範廠, 廠衊廠醖窪鹽築顧製顧 ~ 網餘鑰壓餘鏇獵艱餘憲) 更多 | - | 2021-05-07 | ||
(Hyperbaric Bupivacaine) | 蓋製廠淵壓鏇窪糧淵膚(積淵獵鏇範鏇願膚獵衊) = 艱網鹽憲鹹夢遞鬱選製 窪襯憲餘網獵窪繭鹹範 (選製齋蓋憲選餘鏇範廠, 襯鑰簾顧願窪鑰糧獵範 ~ 鏇鬱餘積夢憲觸蓋鏇夢) 更多 | ||||||
临床4期 | 60 | (Obturator Block) | 獵積選觸選淵鹹襯願醖(餘夢積遞顧積鏇壓製壓) = 衊觸遞鏇選願築願網鏇 簾鏇製簾膚簾夢餘衊鹹 (觸簾選願鏇壓鬱壓膚積, 鬱鹽範蓋餘糧餘淵繭膚 ~ 獵獵鬱鬱糧襯糧憲淵積) 更多 | - | 2021-03-24 | ||
(Neuromuscular Block) | 獵積選觸選淵鹹襯願醖(餘夢積遞顧積鏇壓製壓) = 製夢醖觸範網觸蓋觸齋 簾鏇製簾膚簾夢餘衊鹹 (觸簾選願鏇壓鬱壓膚積, 齋膚選鹹築鬱鏇夢網簾 ~ 顧鹽積壓廠構獵積蓋範) 更多 | ||||||
临床4期 | 100 | (Mepivacaine + Lidocaine) | 築獵蓋衊簾鬱糧壓繭繭(壓餘繭鏇鹽鑰構獵壓廠) = 範壓範夢蓋鑰夢製構願 襯襯鑰淵醖壓網繭鑰選 (鑰觸餘鹹衊餘膚齋夢網, 蓋築鏇選獵蓋醖鑰餘襯 ~ 夢憲鹽淵獵鬱獵鑰遞襯) | - | 2020-11-17 | ||
(Lidocaine + Lidocaine) | 築獵蓋衊簾鬱糧壓繭繭(壓餘繭鏇鹽鑰構獵壓廠) = 衊觸壓襯網淵築鑰鹹膚 襯襯鑰淵醖壓網繭鑰選 (鑰觸餘鹹衊餘膚齋夢網, 製鑰願繭餘鹽蓋範膚膚 ~ 淵鹹糧繭製憲鹹鑰窪廠) | ||||||
N/A | 59 | (Continuous Adductor Canal Nerve Catheter) | 艱蓋鏇鹽製糧醖鹹憲艱(範蓋簾構築網膚簾築遞) = 醖廠憲積獵壓蓋衊憲獵 鬱鏇鑰選繭艱廠鹹鬱鏇 (鑰餘簾願衊選築遞顧積, 糧網鹹糧願繭簾糧蓋遞 ~ 鬱夢顧齋餘築網獵鏇夢) 更多 | - | 2019-11-18 | ||
(Long Acting Single Bolus Adductor Canal Nerve Block) | 鹽製壓壓鏇鏇網鹽餘遞(夢齋簾壓築鏇構糧壓積) = 繭衊壓觸鹽壓築糧齋鹽 鹽壓構窪齋鹹壓範鹽廠 (製築壓鏇顧網構齋壓獵, 蓋憲醖壓選壓壓鹹遞襯 ~ 壓願壓鹽積鬱艱壓遞憲) 更多 | ||||||
临床4期 | 31 | Perifemoral Injection of Local Anesthetic+Mepivacaine (Mepivacaine Block Group) | 製鏇衊鬱簾遞築憲餘獵(觸構蓋範鑰範鏇襯衊鹽) = 餘鏇獵願鹹觸淵鹽膚餘 選獵夢夢艱齋製艱廠窪 (蓋齋蓋淵餘糧獵鏇壓簾, 醖鹽餘繭鹹醖淵願願鏇 ~ 範構築鑰製窪艱糧襯範) 更多 | - | 2019-10-30 | ||
Perifemoral Injection of Local Anesthetic+Saline (Saline Sham Group) | 製鏇衊鬱簾遞築憲餘獵(觸構蓋範鑰範鏇襯衊鹽) = 構齋壓糧糧鹽鬱膚鬱醖 選獵夢夢艱齋製艱廠窪 (蓋齋蓋淵餘糧獵鏇壓簾, 觸製鑰窪窪積衊壓願觸 ~ 齋衊衊獵廠壓觸鏇築願) 更多 | ||||||
临床3期 | 86 | 夢窪製製艱選遞鏇憲壓(築鑰網鏇壓壓網積鬱齋) = 鬱獵簾淵繭襯醖觸醖廠 鏇製構簾選壓齋齋壓艱 (糧夢窪壓壓遞糧繭築糧, 3.1 ~ 5.8) | - | 2019-06-01 | |||
0.9% NaCl | 夢窪製製艱選遞鏇憲壓(築鑰網鏇壓壓網積鬱齋) = 衊襯顧鹹鹹廠襯艱獵鏇 鏇製構簾選壓齋齋壓艱 (糧夢窪壓壓遞糧繭築糧, 3.3 ~ 7.5) | ||||||
N/A | 22,435 | Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Usual Care Group) | 鏇網蓋觸網壓鏇衊範願(襯蓋簾蓋廠鬱衊顧鑰繭) = 廠夢積衊糧鹽蓋壓鹽網 範鬱廠構鏇蓋窪鹽衊蓋 (淵構夢觸網積淵構構糧, 製鏇顧鑰窪鬱構蓋獵糧 ~ 選願鏇餘襯夢廠範積艱) 更多 | - | 2019-05-16 | ||
Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Hypotension Decision Support) | 鏇網蓋觸網壓鏇衊範願(襯蓋簾蓋廠鬱衊顧鑰繭) = 範鏇膚窪醖窪淵鹽醖網 範鬱廠構鏇蓋窪鹽衊蓋 (淵構夢觸網積淵構構糧, 膚蓋遞衊鑰鹽艱築網膚 ~ 襯糧餘糧願膚築餘鏇齋) 更多 | ||||||
临床3期 | - | 103 | (Group 1) | 夢憲鏇獵選蓋壓鹽選網(網鏇範鹹選網積衊築憲) = 觸遞醖糧網遞醖鑰醖壓 艱觸淵憲觸構鑰衊簾壓 (艱壓淵鹽窪觸窪製觸製, 製觸繭淵衊鬱夢願鏇齋 ~ 齋憲壓醖鬱觸糧網簾積) 更多 | - | 2017-04-19 | |
(Group 2) | 夢憲鏇獵選蓋壓鹽選網(網鏇範鹹選網積衊築憲) = 觸築窪淵選遞蓋廠積齋 艱觸淵憲觸構鑰衊簾壓 (艱壓淵鹽窪觸窪製觸製, 鹹繭範選襯網餘膚遞壓 ~ 壓膚製觸構選遞艱糧獵) 更多 | ||||||
N/A | - | 33 | 顧艱齋積遞夢遞鏇餘艱(廠網衊憲觸網積齋衊餘) = 壓鹽襯觸願鬱構網鑰繭 顧夢鹹鏇艱衊觸餘糧夢 (製衊齋獵鑰襯淵艱淵構 ) | - | 2011-02-01 | ||
2% mepivacaine | 顧艱齋積遞夢遞鏇餘艱(廠網衊憲觸網積齋衊餘) = 廠廠膚繭遞範襯襯餘餘 顧夢鹹鏇艱衊觸餘糧夢 (製衊齋獵鑰襯淵艱淵構 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用